Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Merchan · SciRah

Researcher profile · Semantic Scholar

J. Merchan

Share profile

J. Merchan — researcher profile on SciRah

h-index: 38
Works: 177
Citations: 13K

Most-cited papers

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
R. Motzer, B. Alekseev, S. Rha, C. Porta +34 more
2021New England Journal of Medicine1,326 citations Open access
Semantic Scholar
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
B. Wilky, M. Trucco, T. Subhawong, V. Florou +11 more
2019The Lancet Oncology315 citations
Semantic Scholar
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
T. Choueiri, T. Bauer, K. Papadopoulos, E. Plimack +8 more
2021Nature Medicine265 citations Open access
Semantic Scholar
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
C. Hoimes, T. Flaig, M. Milowsky, T. Friedlander +11 more
2022Journal of Clinical Oncology229 citations Open access
Semantic Scholar
Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets
S. K. Tan, H. Hougen, J. Merchan, M. Gonzalgo +1 more
2022Nature reviews. Urology170 citations
Semantic Scholar
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
T. Choueiri, M. Eto, Robert J. Motzer, U. de Giorgi +24 more
2023The Lancet Oncology131 citations Open access
Semantic Scholar
Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma.
G. Narayanan, P. Hosein, Isabelle C. Beulaygue, T. Froud +10 more
2017Journal of Vascular and Interventional Radiology118 citations
Semantic Scholar
Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
J. Rosenberg, T. Flaig, T. Friedlander, M. Milowsky +8 more
2020Journal of Clinical Oncology98 citations
Semantic Scholar
Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma.
M. Khushman, N. Dempsey, J. Maldonado, A. Loaiza-Bonilla +19 more
2015Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]71 citations
Semantic Scholar
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
T. Choueiri, D. McDermott, J. Merchan, T. Bauer +10 more
2023The Lancet Oncology68 citations
Semantic Scholar
Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma
C. Even, U. Lassen, J. Merchan, C. le Tourneau +9 more
2019Investigational new drugs66 citations Open access
Semantic Scholar
EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
C. Hoimes, J. Rosenberg, S. Srinivas, D. Petrylak +8 more
2019Annals of Oncology50 citations Open access
Semantic Scholar
Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers.
J. Luke, J. Powderly, J. Merchan, M. Barve +7 more
2019Journal of Clinical Oncology38 citations
Semantic Scholar
Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).
J. Rosenberg, S. Sridhar, Jing-Song Zhang, David C. Smith +15 more
201838 citations
Semantic Scholar
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors
C. Rudin, H. Pandha, M. Zibelman, W. Akerley +17 more
2023Journal for ImmunoTherapy of Cancer35 citations Open access
Semantic Scholar
Targeting tumor vasculature through oncolytic virotherapy: recent advances
Marcela Toro Bejarano, J. Merchan
2015Oncolytic Virotherapy35 citations Open access
Semantic Scholar
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors
A. Azaro, C. Massard, W. Tap, P. Cassier +8 more
2021Investigational new drugs34 citations
Semantic Scholar
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
Richard A. Miller, J. Luke, Shenshen Hu, S. Mahabhashyam +5 more
2022Journal for ImmunoTherapy of Cancer32 citations Open access
Semantic Scholar
Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).
T. Choueiri, E. Plimack, T. Bauer, J. Merchan +7 more
202032 citations
Semantic Scholar
Molecular Effects of Stromal Selective Targeting by uPAR Retargeted Oncolytic Virus in Breast Cancer
Yuqi Jing, Valery Chavez, Yu-Guang J. Ban, Nicolas Acquavella +4 more
2017Molecular Cancer Research32 citations Open access
Semantic Scholar
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
R. Motzer, C. Porta, M. Eto, T. Powles +16 more
2023Journal of Clinical Oncology31 citations
Semantic Scholar
Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours.
O. Mir, A. Azaro, J. Merchan, R. Chugh +11 more
2018European Journal of Cancer28 citations
Semantic Scholar
Combining 2-deoxy-D-glucose with fenofibrate leads to tumor cell death mediated by simultaneous induction of energy and ER stress
Huaping Liu, M. Kurtoğlu, Clara Lucía León-Annicchiarico, C. Muñoz-Pinedo +5 more
2016OncoTarget28 citations Open access
Semantic Scholar
Biomarker analyses from the phase 3 randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
R. Motzer, C. Porta, M. Eto, T. Hutson +16 more
2024Annals of Oncology25 citations Open access
Semantic Scholar
Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).
L. Harshman, Michael P. Chu, S. George, B. Hughes +7 more
202025 citations
Semantic Scholar
The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.
T. Bauer, T. Choueiri, K. Papadopoulos, E. Plimack +8 more
202123 citations
Semantic Scholar
Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
R. Motzer, C. Porta, M. Eto, T. Powles +16 more
202123 citations
Semantic Scholar
Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.
B. Rini, L. Appleman, R. Figlin, E. Plimack +6 more
2019Journal of Clinical Oncology22 citations
Semantic Scholar
Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).
J. Rosenberg, S. Sridhar, Jing-Song Zhang, David C. Smith +15 more
2019Journal of Clinical Oncology22 citations
Semantic Scholar
Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.
Shilpa Gupta, J. Rosenberg, R. McKay, T. Flaig +15 more
2023Journal of Clinical Oncology20 citations
Semantic Scholar
Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
J. Rosenberg, T. Flaig, T. Friedlander, M. Milowsky +8 more
2020Journal of Clinical Oncology17 citations
Semantic Scholar
A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC
E. Jonasch, E. Plimack, T. Bauer, J. Merchan +7 more
2019Annals of Oncology15 citations Open access
Semantic Scholar
IN VIVO ANTITUMOR ACTIVITY BY DUAL STROMAL AND TUMOR TARGETED ONCOLYTIC MEASLES VIRUSES
Yuqi Jing, Valery Chavez, Natasha K. Khatwani, Yu-Guang J. Ban +3 more
2020Cancer Gene Therapy14 citations Open access
Semantic Scholar
SAFETY AND ACTIVITY OF TEMSIROLIMUS AND BEVACIZUMAB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA PREVIOUSLY TREATED WITH TYROSINE KINASE INHIBITORS: A PHASE 2 CONSORTIUM STUDY
J. Merchan, R. Qin, H. Pitot, J. Picus +6 more
2015Cancer Chemotherapy and Pharmacology14 citations Open access
Semantic Scholar
The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma.
S. Palacio, P. Hosein, I. Reis, I. Akunyili +6 more
2018Journal of Gastrointestinal Oncology13 citations Open access
Semantic Scholar
Relationship of infusion duration to safety, efficacy, and pharmacodynamics (PD): Second part of a phase I-II study using VSV-IFNβ-NIS (VV1) oncolytic virus in patients with refractory solid tumors.
J. Merchan, M. Patel, T. Cripe, M. Old +10 more
202012 citations
Semantic Scholar
A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS).
B. Wilky, M. Trucco, D. Kolonias, E. Wieder +10 more
201812 citations
Semantic Scholar
Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)
J. Rosenberg, E. Heath, R. Perez, J. Merchan +13 more
201612 citations Open access
Semantic Scholar
Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
R. Motzer, S. George, J. Merchan, T. Hutson +5 more
2023The Oncologist10 citations Open access
Semantic Scholar
A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.
M. Mobasher, Richard A. Miller, L. Kwei, D. Strahs +8 more
2019Journal of Clinical Oncology9 citations
Semantic Scholar
Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC).
C. Even, U. Lassen, J. Merchan, C. le Tourneau +8 more
20178 citations
Semantic Scholar
Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).
J. Rosenberg, E. Heath, P. Van Veldhuizen, J. Merchan +14 more
20167 citations
Semantic Scholar
Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.
N. Mar, T. Friedlander, C. Hoimes, T. Flaig +13 more
2020Journal of Clinical Oncology6 citations
Semantic Scholar
Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.
D. Petrylak, David C. Smith, T. Flaig, Jing-Song Zhang +16 more
20186 citations
Semantic Scholar
Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
C. Curran, E. Adib, V. Kazakova, P. Grivas +10 more
2021Clinical Genitourinary Cancer5 citations
Semantic Scholar
AI-Assisted chemical probe discovery for the understudied Calcium-Calmodulin Dependent Kinase, PNCK
Derek J. Essegian, Valery Chavez, Rabia Khurshid, J. Merchan +1 more
2022bioRxiv4 citations Open access
Semantic Scholar
Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).
E. Adib, R. Jain, W. P. Skelton, D. Freeman +10 more
20214 citations
Semantic Scholar
Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
T. Choueiri, T. Bauer, K. Papadopoulos, E. Plimack +8 more
2021Nature Medicine4 citations Open access
Semantic Scholar
A Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors
A. Montero, D. Kwon, A. Flores, K. Kovács +4 more
2016Clinical Cancer Research4 citations Open access
Semantic Scholar
701 Activating CD73 on B cells as a target for immunotherapy of COVID-19 and viral associated cancers: clinical activity in human papilloma virus positive (HPV) head and neck squamous cell cancers (HNSCC)
J. Luke, J. Merchan, B. Hughes, J. Sosman +11 more
2021Journal for ImmunoTherapy of Cancer3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Choueiri×12
Invite
T. Choueiri — researcher profile on SciRah
J. Rosenberg×12
Invite
J. Rosenberg — researcher profile on SciRah
E. Plimack×9
Invite
E. Plimack — researcher profile on SciRah
T. Flaig×9
Invite
T. Flaig — researcher profile on SciRah

×9

Invite

M. Milowsky — researcher profile on SciRah

Invite

S. Srinivas — researcher profile on SciRah

Invite

D. Petrylak — researcher profile on SciRah

Invite

R. Perini — researcher profile on SciRah

D. McDermott×7

Invite

D. McDermott — researcher profile on SciRah

Invite

T. Bauer — researcher profile on SciRah

M. Michaelson×6

Invite

M. Michaelson — researcher profile on SciRah

Invite

L. Appleman — researcher profile on SciRah